Alchemab bags fresh round of in­vestors for tar­get-ag­nos­tic an­ti­body de­vel­op­ment for Hunt­ing­ton's, Covid-19

With a “tar­get-ag­nos­tic” ap­proach to an­ti­body de­vel­op­ment, the UK’s Alchemab has used lessons learned from pa­tients with re­sis­tance to cer­tain dis­eases to chase af­ter con­di­tions as far apart as Hunt­ing­ton’s and Covid-19. Now, in­vestors are jump­ing on board the con­cept with an $86 mil­lion Se­ries A.

The pro­ceeds will go to­ward ad­vanc­ing the com­pa­ny’s tar­get-ag­nos­tic drug dis­cov­ery pro­gram, a re­lease said. That ap­proach looks at the an­ti­body reper­toires of pa­tients who show re­sis­tance to typ­i­cal­ly de­struc­tive dis­eases re­gard­less of ge­net­ic dis­po­si­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER